

MarÃ-a L De Ceballos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9128869/publications.pdf>

Version: 2024-02-01

80
papers

5,066
citations

126708

33
h-index

88477

70
g-index

83
all docs

83
docs citations

83
times ranked

6902
citing authors

#	ARTICLE	IF	CITATIONS
1	Insulin regulates neurovascular coupling through astrocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	16
2	Amyloid- β 1-40 differentially stimulates proliferation, activation of oxidative stress and inflammatory responses in male and female hippocampal astrocyte cultures. <i>Mechanisms of Ageing and Development</i> , 2021, 195, 111462.	2.2	8
3	Targeting Cannabinoid Receptor Activation and BACE-1 Activity Counteracts TgAPP Mice Memory Impairment and Alzheimer's Disease Lymphoblast Alterations. <i>Molecular Neurobiology</i> , 2020, 57, 1938-1951.	1.9	8
4	Indazolylketones as new multitarget cannabinoid drugs. <i>European Journal of Medicinal Chemistry</i> , 2019, 166, 90-107.	2.6	16
5	Sex differences in the phagocytic and migratory activity of microglia and their impairment by palmitic acid. <i>Glia</i> , 2018, 66, 522-537.	2.5	83
6	The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. <i>Neuropharmacology</i> , 2017, 116, 174-187.	2.0	23
7	Boosting brain glucose metabolism to fight neurodegeneration?. <i>Oncotarget</i> , 2017, 8, 14273-14274.	0.8	7
8	Effects of Video Game Training on Behavioral and Electrophysiological Measures of Attention and Memory: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2017, 6, e8.	0.5	11
9	Vascular Dysfunction in a Transgenic Model of Alzheimer's Disease: Effects of CB1R and CB2R Cannabinoid Agonists. <i>Frontiers in Neuroscience</i> , 2016, 10, 422.	1.4	14
10	Ghrelin Regulates Glucose and Glutamate Transporters in Hypothalamic Astrocytes. <i>Scientific Reports</i> , 2016, 6, 23673.	1.6	62
11	Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. <i>Autophagy</i> , 2016, 12, 1902-1916.	4.3	300
12	Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease. <i>Neuropharmacology</i> , 2016, 110, 519-529.	2.0	43
13	Cannabinoids for the treatment of neuroinflammation. , 2015, , 3-14.		4
14	Preliminary research on 1-(4-bromo-2-nitroimidazol-1-yl)-3-[18 F]fluoropropan-2-ol as a novel brain hypoxia PET tracer in a rodent model of stroke. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 604-615.	2.6	6
15	Normal aging in rats and pathological aging in human Alzheimer's disease decrease FAAH activity: Modulation by cannabinoid agonists. <i>Experimental Gerontology</i> , 2014, 60, 92-99.	1.2	36
16	Leptin gene therapy attenuates neuronal damages evoked by amyloid- β and rescues memory deficits in APP/PS1 mice. <i>Gene Therapy</i> , 2014, 21, 298-308.	2.3	64
17	Impaired hippocampal glucoregulation in the cannabinoid CB1 receptor knockout mice as revealed by an optimized in vitro experimental approach. <i>Journal of Neuroscience Methods</i> , 2012, 204, 366-373.	1.3	6
18	Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β -amyloid levels and improves cognitive performance in Tg APP 2576 mice. <i>Journal of Neuroinflammation</i> , 2012, 9, 8.	3.1	196

#	ARTICLE	IF	CITATIONS
19	Leptin regulates glutamate and glucose transporters in hypothalamic astrocytes. <i>Journal of Clinical Investigation</i> , 2012, 122, 3900-3913.	3.9	168
20	Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. <i>Brain</i> , 2011, 134, 1041-1060.	3.7	164
21	Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease. <i>Molecular Pharmacology</i> , 2011, 79, 964-973.	1.0	305
22	Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. <i>Glia</i> , 2010, 58, 588-598.	2.5	301
23	Central Levodopa Influx and the Clinical Motor Response to Levodopa in Patients With Parkinson Disease Complicated With Motor Fluctuations and Dyskinesias. <i>Clinical Neuropharmacology</i> , 2009, 32, 321-325.	0.2	2
24	Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by DOPA. <i>European Journal of Neuroscience</i> , 2008, 27, 580-592.	1.2	89
25	Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions. <i>Neuroscience</i> , 2008, 152, 734-740.	1.1	30
26	The Transcription Factor Nrf2 Is a Therapeutic Target against Brain Inflammation. <i>Journal of Immunology</i> , 2008, 181, 680-689.	0.4	424
27	Endocannabinoids in Alzheimer's Disease. , 2008, , 395-405.		0
28	Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation. <i>Journal of Neuroscience</i> , 2005, 25, 1904-1913.	1.7	670
29	The role of cannabinoids in preventing the neurodegenerative process occurring in Alzheimer's disease. <i>Drugs of the Future</i> , 2005, 30, 807.	0.0	3
30	Functional responses to the cannabinoid agonist WIN 55,212-2 in neonatal rats of both genders: influence of weaning. <i>Pharmacology Biochemistry and Behavior</i> , 2004, 78, 593-602.	1.3	16
31	A β -Amyloid ₂₅₋₃₅ inhibits glutamate uptake in cultured neurons and astrocytes: modulation of uptake as a survival mechanism. <i>Neurobiology of Disease</i> , 2004, 15, 580-589.	2.1	67
32	Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier GLUT-1 Electronic supplementary information (ESI) available: experimental details for the preparation of all derivatives and biological assays. See http://www.rsc.org/suppdata/ob/b2/b212066f/ . <i>Organic and Biomolecular Chemistry</i> , 2003, 1, 767-771.	1.5	69
33	Cannabinoids Protect Astrocytes from Ceramide-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway. <i>Journal of Biological Chemistry</i> , 2002, 277, 36527-36533.	1.6	145
34	Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid A β -peptide. <i>Neuroscience Letters</i> , 2002, 325, 199-202.	1.0	31
35	The AMP-Activated Protein Kinase Is Involved in the Regulation of Ketone Body Production by Astrocytes. <i>Journal of Neurochemistry</i> , 2002, 73, 1674-1682.	2.1	110
36	Increased cannabinoid CB ₁ receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. <i>European Journal of Neuroscience</i> , 2001, 14, 1827-1832.	1.2	166

#	ARTICLE	IF	CITATIONS
37	Î²-Amyloid-Induced Cytotoxicity, Peroxide Generation and Blockade of Glutamate Uptake in Cultured Astrocytes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001, 39, 317-8.	1.4	6
38	Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. <i>Cancer Research</i> , 2001, 61, 5784-9.	0.4	298
39	Î²-Amyloid Peptides Are Cytotoxic to Astrocytes in Culture: A Role for Oxidative Stress. <i>Neurobiology of Disease</i> , 2000, 7, 395-405.	2.1	53
40	Repeated intracerebroventricular administration of Î²-amyloid 25â€“35 to rats decreases muscarinic receptors in cerebral cortex. <i>Neuroscience Letters</i> , 2000, 278, 69-72.	1.0	28
41	In vivo effects of new inhibitors of catechol-O -methyl transferase. <i>British Journal of Pharmacology</i> , 1999, 126, 1667-1673.	2.7	15
42	Subgroups of parkinsonian patients differentiated by peptidergic immunostaining of caudate nucleus biopsies. <i>Peptides</i> , 1999, 20, 249-257.	1.2	15
43	Alzheimer's disease: relationship between muscarinic cholinergic receptors, Î²â€“amyloid and tau proteins. <i>Fundamental and Clinical Pharmacology</i> , 1998, 12, 473-481.	1.0	42
44	Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. <i>Brain</i> , 1996, 119, 823-830.	3.7	51
45			

#	ARTICLE	IF	CITATIONS
55	Analgésicos dipeptídicos. 7. 3,7-Diamino-2-hidroxiheptanoico ácido (DAHHA) conteniendo dipeptídicos análogos del compuesto analgésico H-Lys-Trp(Nps)-OMe. <i>Journal of Medicinal Chemistry</i> , 1992, 35, 889-895.	2.9	2
56	Efectos de una lesión unilateral de 6-hidroxi dopamina y un tratamiento prolongado con L-3,4-dihidroxi fenilalanina sobre sistemas peptidérgicos en la ganglia basal del ratón. <i>European Journal of Pharmacology</i> , 1992, 219, 183-192.	1.7	56
57	Síntesis e Inhibitorias Actividades contra la Aminopeptidasa B y las Enzimas Degradadoras de Enkefalina de los Análogos de los Arpameninas de la Dipeptídica de Metileno. <i>Archiv Der Pharmazie</i> , 1992, 325, 3-8.	2.1	3

58

#	ARTICLE	IF	CITATIONS
73	Antinociceptive effects in rodents of the dipeptide Lys-Trp (Nps) and related compounds. <i>Peptides</i> , 1986, 7, 39-43.	1.2	12
74	Acute and repeated administration of sulpiride alters Met- and Leu-enkephalin content of rat brain. <i>Neuroscience Letters</i> , 1986, 68, 322-326.	1.0	12
75	Do enkephalins in basal ganglia mediate a physiological motor rest mechanism?. <i>Movement Disorders</i> , 1986, 1, 223-233.	2.2	48
76	Prenatal exposure of rats to antidepressant drugs down-regulates beta-adrenoceptors and 5-HT ₂ receptors in cerebral cortex. <i>Neuropharmacology</i> , 1985, 24, 947-952.	2.0	52
77	Prenatal exposure of rats to antidepressants enhances agonist affinity of brain dopamine receptors and dopamine-mediated behaviour. <i>European Journal of Pharmacology</i> , 1985, 116, 257-262.	1.7	20
78	Chronic antidepressant treatment increases enkephalin levels in n. Accumbens and striatum of the rat. <i>European Journal of Pharmacology</i> , 1985, 112, 119-122.	1.7	63
79	GABA modulation of cholinergic transmission in rat oviduct. <i>Life Sciences</i> , 1984, 35, 357-364.	2.0	9
80	Circannual variation in opioid receptor sensitivity in mouse vas deferens. <i>European Journal of Pharmacology</i> , 1984, 106, 227-228.	1.7	11